The course of the disease is similar to what has been observed in patients with HER2-positive breast cancer treated with the large molecule Trastuzumab, in which malignant breast cancer cells in the CSF were refractory to systemic therapy because this agent does not cross the blood-brain barrier [22]. This evidence concerns the gene ERBB2 and breast cancer.